Meeting
2019 ASCO Annual Meeting
A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Authors
Rutika Mehta
Roswell Park Cancer Institute, Buffalo, NY
Rutika Mehta , Richard D. Kim , Neal Shah , Estrella M. Carballido , Youngchul Kim , Iman Imanirad , Dae Won Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03686488
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4149)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4149
Abstract #
TPS4149
Poster Bd #
250a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab-based therapy: Final results of the phase II RE-ExPEL study.
First Author: Thorsten Oliver Goetze
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).
First Author: Rutika Mehta
Poster
2021 Gastrointestinal Cancers Symposium
Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).
First Author: Yasuyuki Kawamoto
Poster
2023 ASCO Annual Meeting
Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.
First Author: Kohei Shitara